Bayesian Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Bayesian Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,800	Closed	-$147K	–	839
2023 Q2	$147K	Buy	+13,800	New	+$148K	0.02%	668
2022 Q2	–	Sell	-55,100	Closed	-$693K	–	926
2022 Q1	$693K	Buy	+55,100	New	+$632K	0.1%	287
2020 Q2	–	Sell	-21,100	Closed	-$213K	–	645
2020 Q1	$213K	Buy	21,100 +9,400	+80%	+$110K	0.05%	570
2019 Q4	$156K	Buy	+11,700	New	+$129K	0.03%	550
2016 Q3	–	Sell	-17,087	Closed	-$187K	–	427
2016 Q2	$187K	Buy	+17,087	New	+$167K	0.11%	339

Other funds holding IRWD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Bayesian Capital Management's IRWD Position: Q3 2023 in Review

Bayesian Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2023, closing a stake of 13,800 shares — an estimated $147K sold.

Bayesian Capital Management first reported a position in IRWD in Q2 2016 and held it in 5 quarters. The position peaked at $693K in Q1 2022. 248 funds tracked by Wall St. Rank hold IRWD as of Q3 2023.

Bayesian Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Bayesian Capital Management sold 13,800 Ironwood Pharmaceuticals shares in Q3 2023, an estimated $147K.
Bayesian Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2016 and held it in 5 quarters.
Bayesian Capital Management's Ironwood Pharmaceuticals position peaked at $693K in Q1 2022.
248 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.